Sunshine Heart to Attend Upcoming Investor Conferences
February 26 2014 - 5:15AM
Sunshine Heart, Inc. (Nasdaq:SSH) today announced that the company
is scheduled to present a corporate update at the following
upcoming investor conferences in March, 2014:
- Cowen and Company 34th Annual Healthcare
Conference
Presentation: Wednesday, March 5, 2014 at 10:00
AM EST at the Boston Marriott Copley Place in Boston, MA
Breakout Session: 10:40 AM – 11:10 AM EST
- 26th Annual ROTH Conference
Presentation: Monday, March 10, 2014 at 2:00 PM
PST at The Ritz-Carlton in Dana Point, CA in Track 2: Salon 2
- BTIG Inaugural Medical Technology, Diagnostics, &
HCIT Snowbird Conference
Format: One-on-one meetings only from March 18
to 20, 2014 at the Cliff Lodge Snowbird Ski & Summer Resort in
Snowbird, UT
About the C-Pulse® Heart Assist System
The C-Pulse Heart Assist System, or C-Pulse System, an
investigational device in the United States, Canada and countries
that do not recognize the CE mark approval, utilizes the scientific
principles of intra-aortic balloon counterpulsation applied in an
extra-aortic approach to assist the left ventricle by reducing the
workload required to pump blood throughout the body, while
increasing blood flow to the coronary arteries. Combined, these
potential benefits may help sustain the patient's current condition
or, in some cases, reverse the heart failure process, thereby
potentially preventing the need for later-stage heart failure
devices, such as left ventricular assist devices (LVADs),
artificial hearts or transplants. It may also provide relief from
the symptoms of Class III and ambulatory Class IV heart failure and
improve quality of life and cardiac function. Based on the results
from our feasibility trial, we also believe that some patients
treated with our C-Pulse System will be able to stop using the
device due to sustained improvement in their condition as a result
of the therapy. Caution: Investigational device, limited by Federal
(or United States) Law to Investigational use. About
Sunshine® Heart
Sunshine Heart, Inc. (Nasdaq:SSH) is an early-stage medical
device company focused on developing, manufacturing and
commercializing the C-Pulse System for treatment of Class III and
ambulatory Class IV heart failure. Sunshine Heart has completed an
approved U.S. Food and Drug Administration (FDA) feasibility
clinical trial of the C-Pulse System and presented the results in
November 2011. In March 2012, the FDA notified the Company that it
could move forward with an investigational device exemption (IDE)
application. Sunshine Heart received unconditional approval from
the FDA in November 2012 to initiate its pivotal trial. In July
2012, Sunshine Heart received CE Mark approval for its C-Pulse
System in Europe. Sunshine Heart is a Delaware corporation
headquartered in Minneapolis with a wholly owned subsidiary in
Australia. The Company has been listed on the NASDAQ Capital Market
since February 2012.
Forward-Looking Statements
Certain statements in this release are forward-looking
statements that are based on management's beliefs, assumptions,
expectations, and information currently available to management.
All statements that address future operating performance, events or
developments that we expect or anticipate will occur in the future
are forward-looking statements, including, without limitation,
future clinical trial activities and results including patient
enrollment in trials. These forward-looking statements are subject
to numerous risks and uncertainties, including, without limitation,
the possibility that our clinical trials do not meet their
enrollment goals, meet their endpoints or otherwise fail, that
regulatory authorities do not accept our application or approve the
marketing of the C-Pulse System, the possibility that we may be
unable to raise the funds necessary for the development and
commercialization of our products, that we may not be able to
commercialize our products successfully in the EU and the other
risk factors described under the caption "Risk Factors" and
elsewhere in our filings with the SEC. You should not place undue
reliance on forward-looking statements because they speak only as
of the date when made and may turn out to be inaccurate. We do not
assume any obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise. We may not actually achieve the plans,
projections or expectations disclosed in forward-looking
statements, and actual results, developments or events could differ
materially from those disclosed in the forward-looking
statements.
CONTACT: For further information, please contact:
Investor:
Laura Forman
Blueprint Life Science Group
T: +1-415-375-3340
Jeff Mathiesen
Chief Financial Officer
Sunshine Heart, Inc.
T: +1-952-345-4200
Media:
David Schull
Russo Partners
T: +1-212-845-4271
Andreas Marathis
Russo Partners
T: +1-212-845-4235
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Mar 2024 to Apr 2024
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Apr 2023 to Apr 2024